13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
61 檔
28.2%
According to the latest 13F quarterly dataset, Birchview Capital, LP managed an equity portfolio of $213.8M at the end of Q3 2024, spanning 61 distinct U.S. exchange-listed positions.
Birchview Capital, LP executed strategic sector rebalancing during Q3 2024, establishing 5 new positions while fully exiting 4 holdings and trimming 7 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 30.74% | -2.56% | -0.30% | |
| 2 | ✓ | Biodesix Inc | Stock-Other | 8.76% | +0.65% | — | |
| 3 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 5.33% | -0.15% | +59.90% | |
| 4 | ELUT | Elutia Inc | Stock-Other | 4.36% | -0.02% | -14.85% | |
| 5 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.10% | -0.38% | — | |
| 6 | PRTA | Prothena Corporation plc | Stock-Other | 3.04% | -0.42% | +2.95% | |
| 7 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.02% | +0.10% | -28.41% | |
| 8 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 2.97% | +1.25% | — | |
| 9 | HROW | Harrow Inc | Stock-Other | 2.84% | — | -51.39% | |
| 10 | QDELUSD | Quidelortho CORP | Stock-Other | 2.67% | -0.04% | — | |
| 11 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 2.59% | -0.13% | — | |
| 12 | AXGN | Axogen Inc | Stock-Other | 2.39% | — | — | |
| 13 | PHR | Phreesia Inc | Stock-Other | 2.26% | -0.07% | EXIT | |
| 14 | STOK | Stoke Therapeutics Inc | Stock-Other | 2.23% | -1.16% | — | |
| 15 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.87% | -0.09% | — | |
| 16 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.79% | +0.28% | +21.31% | |
| 17 | MASI* | Masimo CORP | Stock-Other | 1.76% | — | — | |
| 18 | OVV | Ovintiv Inc | Stock-Energy | 1.73% | -0.98% | -29.65% | |
| 19 | DCGO | Docgo Inc | Stock-Other | 1.48% | — | +11.96% | |
| 20 | CSTL | Castle Biosciences Inc | Stock-Other | 1.43% | -0.04% | +70.59% | |
| 21 | ALKS | Alkermes plc | Stock-Healthcare | 1.21% | +0.22% | — | |
| 22 | EQT | Eqt CORP | Stock-Energy | 1.10% | -0.39% | — | |
| 23 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.95% | — | +125.00% | |
| 24 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.82% | -0.65% | EXIT | |
| 25 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.65% | — | — | |
| 26 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.59% | — | — | |
| 27 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.50% | +0.85% | — | |
| 28 | ✓ | Accelerate Diagnostics Inc | Stock-Other | 0.48% | — | — | |
| 29 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.46% | +0.07% | — | |
| 30 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.44% | — | +165.15% | |
| 31 | KROS | Keros Therapeutics Inc | Stock-Other | 0.35% | — | — | |
| 32 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.35% | -0.32% | EXIT | |
| 33 | TMCI | Treace Medical Concepts Inc | Stock-Other | 0.34% | — | — | |
| 34 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.34% | -0.11% | — | |
| 35 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.34% | -0.07% | — | |
| 36 | CHRS | Coherus Oncology Inc | Stock-Other | 0.33% | — | +37.78% | |
| 37 | ARVN | Arvinas Inc | Stock-Other | 0.32% | — | — | |
| 38 | PGNY | Progyny Inc | Stock-Other | 0.32% | — | — | |
| 39 | BHVN | Biohaven Ltd. | Stock-Other | 0.32% | — | — | |
| 40 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.31% | +0.11% | — | |
| 41 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.29% | +0.01% | — | |
| 42 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.28% | — | — | |
| 43 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 44 | NVCR | NovoCure Limited | Stock-Healthcare | 0.27% | -1.26% | EXIT | |
| 45 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.27% | — | — | |
| 46 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.26% | — | — | |
| 47 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 48 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.22% | — | — | |
| 49 | XNCR | Xencor Inc | Stock-Other | 0.21% | — | — | |
| 50 | GOSS | Gossamer Bio Inc | Stock-Other | 0.12% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | +4.3% | -0.30% | Trim |
| 2 | ACAD | Acadia Pharmaceuticals Inc | +1.6% | +59.90% | Add |
| 3 | EQT | Eqt CORP | +1.1% | NEW | New buy |
| 4 | AXGN | Axogen Inc | +1.1% | — | Unchanged |
| 5 | FHTX | Foghorn Therapeutics Inc | +0.9% | — | Unchanged |
| 6 | TVTX | Travere Therapeutics Inc | +0.9% | +21.31% | Add |
| 7 | CORT | Corcept Therapeutics Inc | +0.8% | — | Unchanged |
| 8 | CSTL | Castle Biosciences Inc | +0.8% | +70.59% | Add |
| 9 | ✓ | Biodesix Inc | +0.7% | — | Unchanged |
| 10 | QDELUSD | Quidelortho CORP | +0.6% | — | Unchanged |
| 11 | TMCI | Treace Medical Concepts Inc | +0.3% | NEW | New buy |
| 12 | PTGX | Protagonist Therapeutics Inc | +0.3% | — | Unchanged |
| 13 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.3% | +78.26% | Add |
| 14 | INBX | Inhibrx Biosciences Inc | +0.3% | +165.15% | Add |
| 15 | 2655787D | Blueprint Medicines CORP | +0.2% | NEW | New buy |
| 16 | DCGO | Docgo Inc | +0.2% | +11.96% | Add |
| 17 | UTHR | United Therapeutics CORP | +0.2% | — | Unchanged |
| 18 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.1% | — | Unchanged |
| 19 | ✓ | Accelerate Diagnostics Inc | +0.1% | — | Unchanged |
| 20 | ALKS | Alkermes plc | +0.1% | — | Unchanged |
| 21 | ATEC | Alphatec Holdings Inc | +0.1% | +125.00% | Add |
| 22 | WVE | Wave Life Sciences Ltd. | +0.1% | — | Unchanged |
| 23 | ALMS | Alumis Inc | +0.1% | NEW | New buy |
| 24 | QURE | uniQure N.V. | +0.1% | NEW | New buy |
| 25 | BHVN | Biohaven Ltd. | +0.1% | — | Unchanged |
| 26 | TXG | 10x Genomics Inc-class A | +0.1% | — | Unchanged |
| 27 | KROS | Keros Therapeutics Inc | +0.1% | — | Unchanged |
| 28 | BCRX | Biocryst Pharmaceuticals Inc | 0% | — | Unchanged |
| 29 | HALO | Halozyme Therapeutics Inc | 0% | — | Unchanged |
| 30 | PHR | Phreesia Inc | 0% | — | Unchanged |
| 31 | AXSM | Axsome Therapeutics Inc | 0% | — | Unchanged |
| 32 | AM6 | Amicus Therapeutics Inc | — | — | Unchanged |
| 33 | GOSS | Gossamer Bio Inc | — | — | Unchanged |
| 34 | TSVT* | 2seventy Bio Inc | — | -11.22% | Trim |
| 35 | FENG | Phoenix New Media Limited | — | — | Unchanged |
| 36 | XNCR | Xencor Inc | 0% | — | Unchanged |
| 37 | IFRX | InflaRx N.V. | 0% | — | Unchanged |
| 38 | ZNTL | Zentalis Pharmaceuticals Inc | 0% | — | Unchanged |
| 39 | VTYXUSD | Ventyx Biosciences Inc | 0% | — | Unchanged |
| 40 | MASI* | Masimo CORP | 0% | — | Unchanged |
| 41 | LQDA | Liquidia CORP | 0% | — | Unchanged |
| 42 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 43 | OMGBP | Outset Medical Inc | 0% | — | Unchanged |
| 44 | CABA | Cabaletta Bio Inc | 0% | — | Unchanged |
| 45 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 46 | KPTIEUR | Karyopharm Therapeutics Inc | 0% | — | Unchanged |
| 47 | CYTK | Cytokinetics Inc | 0% | — | Unchanged |
| 48 | NVCR | NovoCure Limited | -0.1% | — | Unchanged |
| 49 | ARVN | Arvinas Inc | -0.1% | — | Unchanged |
| 50 | HROW | Harrow Inc | -0.1% | -51.39% | Trim |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 61 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BMY, BIODESIX INC, ACAD) accounted for 28.2% of total reported equity market value during Q3 2024.
Top New Position Initiated
EQT
市值: $1.3M
Top Position Liquidated / Trimmed
SILKUSD
前期市值: $4.3M
During Q3 2024, Birchview Capital, LP's top holdings by market value included BMY (30.7%)、BIODESIX INC (8.8%)、ACAD (5.3%). The largest single position, BMY, represented 30.7% of total portfolio value.
In Q3 2024, Birchview Capital, LP made 25 total portfolio adjustments, initiating 5 new buys, adding to 9 positions, trimming 7 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.